Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arundic acid is a small molecule neuroprotective agent developed primarily as an astrocyte modulator. It acts by inhibiting the synthesis of S100 calcium-binding protein B (S100B) in astrocytes, which is implicated in neuronal injury and death following brain insults such as stroke and neurodegenerative diseases. Arundic acid also exhibits additional mechanisms, including inhibition of cyclooxygenase 2 (COX-2), free radical scavenging, and inhibition of inducible nitric oxide synthase (NOS2). The drug was investigated for acute ischemic stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and muscle weakness but development has been discontinued for these indications[1][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arundic acid.